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Abstract Chronic obstrudive pulmonary disease (COPD) is a condition characterized by progressive airflow limitation 
and decline in lung function. As seen in other developed countries throughout the world, COPD in the U.K. is associated 
with considerable mortality, and morbidity from the disease places a significant burden on the healthcare system and 
society. Despite the obvious burden of COPD in this country, there is a lack of recognition of COPD among the general 
public. Healthcare professionals may also fail to recognize the burden of disease, as shown by underdiagnosis and 
inadequate management. 
A key step in increasing awareness of the burden of COPD is obtaining comprehensive information about the impact of 
the disease on patients, the health service and society.The large-scale international survey, Confronting COPD in North 
America and Europe, aimed to address this need for information, by interviewing patients and physicians in eight countries. 
An economic analysis of patient responses to the survey in the U.K. showed that COPD places a high burden on the 
healthcare system and society, with annual direct costs estimated at f8 19.42 per patient, and indirect cost at f8 19.66 per 
patient, resulting in total per patient costs of f 1639.08. The cost impact of the disease was particularly marked in 
secondary care, as a result of inpatient hospitalizations, amounting to 54% of direct costs. These results suggest that 
reducing patient requirement for hospital care could alleviate the burden of COPD on the U.K. healthcare system.This will 
require considerable improvements to the way the disease is managed by healthcare professionals in primary care, with 
earlier diagnosis and the use of interventions aimed at preventing exacerbations and delaying the progression of disease, 
0 2003 Elsevler Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disease characterized by airflow limitation that is not 
fully reversible. The airtlow limitation is usually both 
progressive and associated with an abnormal 
inflammatory response of the lungs to noxious particles 
and gases, such as tobacco smoke (I). In the U.K., the 
prevalence of COPD has been estimated at I%, rising to 
5% in men aged 65-74 years, and 10% in men over 
75 years (2). Around 600 000 patients have been 
diagnosed with COPD (3): however, this is likely to be an 
underestimate, as only 25% of patients with COPD may 
be diagnosed (2,4). As seen in other developed countries 
throughout the world (5), COPD in the U.K. is associated 
with considerable mortality. Over  30000 people in the 
U.K. die from COPD each year, with nearly 20 times as 
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many deaths from this disease as from asthma (6-9). In 
1999, COPD was the fifth most common cause of 
mortality overall in England and Wales (after coronary 
heart disease, pneumonia, stroke and lung cancer) (6). 
The symptoms of COPD, including progressive 
dyspnoea, chronic cough and sputum production, result 
in significant morbidity and deterioration in quality of life 
(IO-I 3). The impact of COPD on quality of life is 
particularly high in patients experiencing frequent 
exacerbations (acute episodes of worsening symptoms, 
that are often triggered by respiratory infection) (I I), 
though even patients with only mild disease report 
worse health status than healthy people (I 0). Morbidity 
from COPD places a significant burden on the U.K. 
healthcare system, with over I *44 million primary care 
consultations for the disease each year (14). In England in 
2000/ I, there were over IO0 000 hospital admissions and 
I million in patient bed days for COPD (15). The 
pressure placed on the National Health Service is 
particularly acute in the winter months, with a sharp rise 
in emergency admissions for exacerbations of chronic 
respiratory disease, particularly among the elderly (I 6). 
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The total cost of COPD to the U.K. healthcare system 
was estimated at f8 I7 million in I996/7, with an annual 
per patient cost 2.5 times higher for COPD (6781) than 
for asthma (6280) (I 7). Despite this burden, respiratory 
disease has not been defined as a priority in the National 
Strategy for Health (I 8) unlike other serious diseases 
such as cardiac disease or cancer. 
As a major cause of work absenteeism, COPD also has 
a considerable impact on the U.K. economy. It has been 
estimated that around 24 million working days are lost in 
the U.K. each year as a result of COPD (3), accounting 
for 9% of all certified sickness absence (I 9). The annual 
cost to employers and the economy of COPD-related 
lost productivity is over f3.8 billion (3). The overall 
burden of COPD on the U.K. healthcare system and 
economy is likely to increase in the future, as the 
prevalence of this disease is increasing.The prevalence 
rate rose 25% among men and 69% among women 
between 1990 and 1997, reflecting the aging of the 
population and the long-term cumulative effect of past 
smoking behaviour (20). 
Despite the obvious burden of COPD on U.K. society, 
there is a lack of recognition of COPD among the 
general public. In a recent survey by the British Thoracic 
Society, two-thirds of people questioned had never heard 
of COPD (21). This contrasted sharply with public 
awareness about asthma, which was recognized by three 
times as many people as COPD. Lack of awareness about 
COPD meant that the majority of smokers (over 80%) 
did not consult a healthcare professional for a persistent 
cough, one of the early warning signs of the development 
of this disease. Delaying contact with a healthcare 
professional can only add to the burden of COPD, as 
early diagnosis may help target smoking cessation advice. 
Furthermore, early treatment of COPD may help to 
control symptoms, reduce the impact of exacerbations 
and improve quality of life. In addition to the limited 
recognition of COPD in the general public, healthcare 
professionals may fail to recognize the burden of disease, 
as shown by underdiagnosis and inadequate manage- 
ment. The majority of healthcare professionals in the 
U.K., although aware of guideline recommendations, 
report a need for education on the best approaches to 
treatment (22-23). 
A key step in increasing awareness of the burden of 
COPD is obtaining comprehensive information about 
the impact of the disease on patients, the health service 
and society.The large scale survey, Confronting COPD in 
North America and Europe, aimed to address this need for 
information, by interviewing patients and physicians in 
eight countries. The survey highlighted the significant 
impact of COPD symptoms on patient health and quality 
of life, as reported elsewhere (22-23).This paper reports 
the impact of COPD on healthcare resource utilization, 
lost productivity and associated direct and indirect costs 
in the U.K. 
METHODS 
Confronting COPD survey 
The study methodology has been described in depth 
(24). Briefly, the survey involved telephone interviews 
with a sample of 3265 patients and 905 physicians from 
the U.K., the U.S.A., Canada, France, Germany, Italy, the 
Netherlands and Spain. Patient responses to the survey 
questionnaire were used to collect information on 
COPD-related hospitalizations, emergency room visits, 
primary care consultations, specialist visits, treatment, 
and laboratory tests, for the l2-month period prior to 
the survey. In all countries except Germany, these data 
were used to calculate the direct per patient costs of 
COPD. Time lost from work due to COPD was also 
measured, and used to calculate the indirect per patient 
costs associated with the disease. Finally, annual direct, 
indirect and total costs were assessed in terms of 
disease severity and other patient characteristics, 
including sex, smoking status, comorbidity and education 
level. 
Cost calculations 
Unit costs for healthcare resource use and productivity 
loss for the U.K. economic analysis are shown in Table I. 
The cost of an antibiotic course, chest X-ray, com- 
puterized tomography (CT) scan, electrocardiogram 
(ECG) and finger stick test of blood oxygen during an 
inpatient hospitalization were included in the overall 
cost of a hospital stay, and so are excluded from the 
table. Unit costs for time lost from work were 
calculated for patients up to the standard ages of 
retirement in the U.K. (65 years for men and 60 years 
for women). 
RESULTS 
Patient demographics 
The demographics and clinical characteristics of the 
patients included in the U.K. sample of the Confronting 
COPD survey are shown in Table 2.The mean age was 
63 years, and 48.8% were male. Less than half of the 
patients were current smokers, with a mean pack years 
smoking history of approximately 41 years. Almost 
one-third (30%) of patients with COPD were 
undiagnosed (although they met the symptom criteria 
for having chronic bronchitis: persistent coughing with 
phlegm or sputum from the chest for the last 2 years 
or more). Around three-quarters of the patients in the 
survey had self-perceived mild or moderate COPD, 
and half (47%) of all patients thought that their 
condition was well or completely controlled. Over half 
(53%) of the survey respondents reported that they 
had been diagnosed with other serious or chronic 
conditions, including kidney problems (I 9%), arthritis 
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(I 6%), rheumatism (I 2%), asthma (8%), and diabetes 
(6%). More than half of patients in the survey (54%) did 
not enter further or higher education after leaving 
school. 
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FIGURE I. Percentage of patients reporting healthcare resource use/contacts during the I2 months prior to the survey. 
Healthcare resource utilization 
Patients in the U.K. sample of the survey demonstrated 
considerable use of both primary and secondary 
healthcare resources. Most patients (86%) usually went to 
their general practitioner (GP) for the management of 
their condition. The proportion of patients reporting 
scheduled and unscheduled GP visits during the 
I2 months prior to the survey is shown in Fig. I. A total 
of 2639 GP visits for COPD were reported in the 
previous year (Table 3). Of these visits, 88% were 
scheduled (with a mean of 5.8 scheduled visits per patient 
per year) and 12% were unscheduled (mean 0.79 visits 
per patient, with up to I5 unscheduled visits reported).A 
minority (14%) of patients in the U.K. sample said that 
they received specialist care (Fig. I), with 8% of patients 
visiting a respiratory specialist at least three times during 
the year prior to the survey.A total of 333 specialist visits 
were reported, and around 30% of all specialist visits 
were unscheduled. 
One-quarter of patients reported ever being 
hospitalized for COPD, and one in seven patients (I 4%) 
had required an in-patient stay in the last I2 months, with 
I71 visits in total. The maximum number of inpatient 
hospitalizations per patient was 24. In addition, around 
12% of patients had visited the hospital accident and 
emergency (AE) department at least once during the 
previous year because of COPD (Fig. I ,Table 3). 
In the U.K. survey sample, just over half (55%) of the 
patients were taking prescription medication for COPD, 
and the most commonly prescribed medication classes 
were short-acting &-agonists, inhaled corticosteroids, 
anticholinergics, and long-acting &-agonists (Fig. 2). A 
quarter of patients (24.5%) reported using a nebulizer. 
More than half of the patients had received antibiotics 
for respiratory infections (Table 4). One in I2 patients 
had used home oxygen therapy for COPD in the last 
I2 months, and the total number of days of use was 
estimated at 7660 days (with a mean of almost 240 days 
use for each patient using oxygen therapy). Around 
three-fifths of patients (6 I .5%) had an influenza 
vaccination in the past year. 
The use of laboratory tests for COPD was also 
measured by the survey The results showed that chest 
X-rays were the most commonly reported investigation 
(42% of patients reported an X-ray in the last I2 months). 
A minority of patients had received a computerized 
tomography (CT) (also known as computerized axial 
tomography, or CAT) scan, a magnetic resonance imaging 
(MRI) scan, an electrocardiogram (ECG), or a test of blood 
oxygen (Table 5). A total of 900 laboratory tests for 
COPD were reported by U.K. sample (mean 2.2 tests per 
patient). 
Time lost from work 
Over two-fifths (44%) of patients in the U.K. survey were 
below retirement age. One-quarter (24%) of patients 
reported that they were completely prevented from 
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FIGURE 2. Use of regular prescribed medications by patients in the U.K. sample. 
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FIGURE 3. Percentage breakdown of annual direct costs of COPD for the U.K. sample. 
working due to COPD. A further 9% of patients were lost due to COPD in the previous I2 months, with a 
limited in their ability to work, and 5% missed work as a mean of 12-02 days lost per patient (maximum 365 days 
result of their il1ness.A total of 4808 days of work were lost). One in 20 patients (5%) reported that their 
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caregiver missed work due to the patient’s COPD (mean 
0.2 I days lost per patient). The maximum productivity 
loss reported for caregivers was 36 days in the past year. 
Direct costs 
The annual direct per patient cost of COPD in the U.K. 
sample was estimated at f819.42 (e 1270.21) (Fig. 3, 
Table 6). The highest per patient cost of any individual 
healthcare resource was for inpatient hospitalizations 
(f444.60, 8689. IO), which accounted for over half 
(54.3%) of the total direct costs of COPD per patient. 
When the cost of visits to accident and emergency, and 
unscheduled contacts with a GP or specialist, were 
added to inpatient costs, the total per patient cost of 
unscheduled care was estimated at f494.67 (e766.80): 
60% of the total direct costs of COPD to the healthcare 
system. In contrast, scheduled GP and specialist visits 
accounted for just 16.4% of direct per patient costs, with 
treatment for COPD accounting for less than one-fifth 
( 18.6%) of costs. 
Societal cost 
The mean annual cost of patient work loss due to 
COPD was comparable to the direct cost of the 
disease, at an estimated f819.66 (e 1270.48) per 
patient. Adding the indirect cost to the direct cost of 
the disease gave a total societal cost of f 1639.08 
(c2540.68) per patient with COPD. 
Associations between costs and patient 
variables 
The per patient direct, indirect and total societal costs of 
COPD were analysed further, to see if there were any 
relationships between these costs and disease severity, 
patient sex, smoking status, comorbidity, or education 
level. Healthcare costs, indirect costs and overall societal 
costs were considerably higher in patients with severe 
COPD compared with patients with mild or moderate 
COPD (Fig. 4). In addition, both direct and indirect costs 
were higher in male patients than female patients, and 
patients with comorbidities compared with patients 
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FIGURE 4. Annual societal costs of COPD by disease severity. 
without chronic illnesses other than COPD (Table 7). 
The total societal costs of COPD were twice as high in 
patients with comorbidities than in patients without 
comorbidities. Former smokers and less educated 
patients were more costly to the healthcare system than 
current smokers or well-educated patients, but the 
opposite was the case for economic costs resulting from 
time lost from work (Table 7). 
DISCUSSION 
Patient responses to the Confronting COPD survey 
were used to quantify the impact of the disease in the 
U.K.The survey measured healthcare resource utilization 
and lost productivity in patients with diagnosed COPD 
(including chronic bronchitis and emphysema), and 
patients with symptoms of chronic bronchitis (persistent 
coughing with sputum production for at least 2years) 
who remained undiagnosed. Estimates of direct, indirect 
and total societal costs per patient were also calculated. 
The results of the health economic analysis of the U.K. 
survey sample suggest that COPD places a high burden on 
the healthcare system.The direct cost of the disease was 
estimated at over f819 per patient per year. This cost is 
similar to the cost of COPD reported by a previous 
analysis (f781) and 2.5 times higher than the estimated 
direct per patient cost of asthma (f280) in this country (3). 
The indirect cost of the disease was also estimated at 
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around f8 I9 per patient per year, suggesting that COPD 
has a considerable impact on the economy, as a cause of 
patient absence from work As the calculation of the 
indirect cost of COPD did not include the cost of caregiver 
work loss, it is likely that the real impact of COPD on the 
economy may have been underestimated by this survey. 
The majority of direct per patient costs resulting from 
COPD were due to unscheduled emergency care 
(inpatient hospitalizations, visits to accident and 
emergency, unscheduled contacts with a GP or specialist). 
This type of care may reflect poor disease control, with 
inadequate management of symptoms and acute disease 
exacerbations resulting in unscheduled use of healthcare 
resources. In this study, the cost of inpatient 
hospitalization was three times higher than the cost of 
scheduled healthcare professional contacts. These results 
suggest that the burden of COPD on the healthcare 
system could be alleviated by reducing patient 
requirement for hospital care i.e. by increasing the 
proportion of patients receiving effective treatment 
through scheduled contacts with healthcare professionals. 
The responses of the U.K. sample showed that the vast 
majority of patients were in contact with a primary care 
practitioner for the management of COPD, and a further 
13% of patients were under the care of a specialist, either 
in primary care or the hospital outpatient department. 
However, three out of ten patients in the survey sample 
had not received a diagnosis of COPD (despite having 
chronic bronchitis as defined by symptom criteria), 
suggesting that the disease was underdiagnosed by 
healthcare professionals. A factor that may contribute to 
the underdiagnosis of COPD in this country was 
suggested by a recent survey, which revealed a lack of 
awareness about COPD in the U.K. population (21). 
Poor recognition of the disease may lead patients to 
believe that their respiratory symptoms are nothing 
more than a smoker’s cough, rather than an early sign of 
disease pathology, causing them to delay contact with a 
healthcare professional. 
In addition to underdiagnosis, the results of the U.K. 
survey suggested that patients with COPD were being 
undertreated. Only 55% of patients were receiving 
prescribed medication for COPD, and less than half of 
the patients believed that their condition was completely 
or well controlled.The extent of antibiotic use among 
the survey (reported by 55% of patients) was testimony 
to the high frequency of COPD exacerbations 
experienced in the survey sample, providing another 
indication of poor disease control. 
These results suggest that there is considerable scope 
for improvement in the management of COPD by 
healthcare professionals in the U.K. Raising awareness of 
COPD among the general population could help to 
ensure that the disease is diagnosed in its early stages. 
Early diagnosis is important for the introduction of 
smoking cessation interventions, to delay the 
progression of disease.This could reduce the impact of 
COPD on the healthcare system and society by reducing 
the costs associated with the treatment of severe disease 
(which are considerably higher than the costs of treating 
mild or moderate COPD). Once diagnosed, patients 
need to be prescribed appropriate medication for 
COPD. At present, treatment options for COPD focus 
on bronchodilators, which are able to increase lung 
function and improve symptom control.As such, these 
treatments may reduce the impact of COPD on the 
patient and the healthcare system in terms of 
unscheduled visits to healthcare professionals. However, 
bronchodilators have only a limited impact on the rate 
and severity of disease exacerbations which, as a major 
cause of inpatient hospitalizations, are a main driver of 
direct costs (25). Medications that may act upon the 
underlying inflammatory processes of the disease may 
reduce the frequency and severity of exacerbations and 
could have an important role to play in reducing the 
burden of COPD in the U.K.While treatment guidelines 
recommend influenza vaccination as an important 
strategy for the prevention of exacerbations in patients 
diagnosed with COPD, less than half of the patients in 
the survey had been vaccinated in the previous year. 
Again, these results highlight the need to promote better 
management of COPD in primary care. 
Using the data obtained from the survey, the annual 
cost of COPD to U.K. society was calculated at f I638 
per patient. By applying this cost to the number of 
patients with COPD in this country, it is possible to 
estimate the overall cost of the disease to society. Using 
figures for diagnosed COPD (600000 patients in the 
U.K.) (3) the cost of the disease would amount to f982 
million. However, this may underestimate the real 
economic impact of the disease, as it does not include 
patients who remain undiagnosed.Although not designed 
as a prevalence survey, the information obtained from 
Confronting COPD in the U.K. puts the prevalence of 
diagnosed COPD, chronic bronchitis and emphysema 
plus undiagnosed chronic bronchitis at 6.3%. Applying 
this prevalence rate to the number of people in the U.K. 
population over the age of 45 years (20.7 million in mid 
2000) (26) it is suggested that the total number of 
patients with COPD may be closer to I .3 million, 
bringing the total societal cost of the disease to f2. I 
billion in the U.K. 
CONCLUSION 
The results of the health economic analysis of the U.K. 
survey sample showed that COPD places a high burden 
on the healthcare system and society.The cost impact of 
the disease was particularly marked in secondary care, as 
a result of inpatient hospitalizations. These results 
suggest that reducing patient requirement for hospital 
care could alleviate the burden of COPD on the U.K. 
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healthcare system. To achieve this, the diagnosis and 
treatment of COPD in primary care needs to be 
improved. Interventions aimed at preventing 
exacerbations and delaying the progression of disease 
may reduce the impact of COPD in this country. 
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